Long-term safety in the open-label period of a phase 2a study of brazikumab, an antibody against interleukin-23

Authors
Category Primary study
ConferenceUnited European Gastroenterology Journal
Year 2018
This article has no abstract
Epistemonikos ID: da41259b9f914762e3615b3e8f5c5397df50bbfb
First added on: Apr 29, 2026